Update-Pathogens of concern

Disease-a-Month

Volumn 59, Issue 12, 2013, Pages 437-438

  McFee, Robin B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CAPREOMYCIN; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; KANAMYCIN; PYRIDOXINE; QUINOLONE DERIVATIVE; RIFAMPICIN;

BACTERIAL STRAIN; BACTERIUM DETECTION; DRUG COST; DRUG POTENCY; DRUG RESISTANT TUBERCULOSIS; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MEDICATION COMPLIANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NUTRITIONAL STATUS; PANDEMIC; PUBLIC HEALTH; REVIEW; TREATMENT DURATION; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; CLINICAL PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; GUIDELINE ADHERENCE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTIONS; PUBLIC HEALTH; TUBERCULOSIS;

EID: 84889078105     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2013.10.006     Document Type: Review

References (6)

1. World Health Organization Tuberculosis Fact Sheet. https://who.int.
2. Norbis L., Miotto P., Alagna R., Cirillo D.M. Tuberculosis: lights and shadows in the current diagnostic landscape. New Microbiol 2013, 36(2):111-120.
3. Chang K.C., Yew W.W., Tam C.M., Leung C.C. WHO Group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013, 57(9):4097-4104.
4. WHO notified MDR-TB cases (absolute numbers). World Health Organization. ; 2011 Accessed 07.12.13. https://extranet.who.int/sree/Reports?op=vs&path=/who_hq_reports/g2/prod/ext/m.
5. Tuberculosis and Air Travel: Guidelines for Prevention and Control. 3rd ed. WHO Guidelines, WHO 2008.
6. Mele A., Bilancio G., Luciani R., et al. Atypical mycobacterial infection after kidney transplant: two clinical cases. G Ital Nefrol 2013, 30(1). pii: gin/30.1.